Phaseline

Targets › CYP2C19

CYP2C19 (Cytochrome P450 2C19): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Oncology; next expected readout Mar 2027.

A cytochrome P450 monooxygenase involved in the metabolism of polyunsaturated fatty acids (PUFA). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase). (UniProt, P33261)

Open in Phaseline: the race on CYP2C19, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
The University of Queenslandvoriconazole
Cytochrome P450 51 inhibitor
CYP2C19Phase 2Fungal InfectionMar 2027

Conditions

Fungal Infection (1)

Modalities

–

Companies

The University of Queensland (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.